

Osocimab

Cat. No.:	HY-P99794
CAS No.:	2056878-75-0
Target:	Factor Xa
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Osocimab (BAY 1213790), an anti-FXIa antibody ($K_i=2.4$ nM; $EC_{50}=0.2$ nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects ^[1] .
In Vitro	Osocimab (1.4 nM-1 μ M; 30 min) inhibits thrombin generation, and also inhibits FXIa-mediated activation of FIX (FIX conversion) ($IC_{50}=16$ nM) and FXIa mediated substrate cleavage ($IC_{50}=1.2$ nM) in human plasma ^[1] . Osocimab (22.05 mg/mL) inhibits intrinsic pathway-mediated activation of the coagulation cascade ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Schaefer M, et al. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol. 2019 Dec 6;431(24):4817-4833.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA